FDA Green-Lights ViroPharma’s Cinryze, rHUPH20 Studies
The FDA is allowing ViroPharma and Halozyme Theraputics to move forward with clinical studies of subcutaneous Cinryze in combination with the human hyaluronidase enzyme rHuPH20 to prevent angioedema attacks.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.